GSK Overall Survival Data Clinches Role For BRAF/MEK Combo In Melanoma
This article was originally published in Pharmaceutical Approvals Monthly
In the COMBI-v study, BRAF/MEK combination Tafinlar/Mekinist improves overall survival by 31% compared to BRAF monotherapy. GSK’s combination and Genentech’s cobimetinib/Zelboraf combination both improve progression-free survival and reduce cutaneous malignancies compared to monotherapy.
You may also be interested in...
FDA’s approval of Merck’s anti-PD-1 drug pembrolizumab in melanoma marks a major milestone for oncology and industry’s immune checkpoint efforts. But with an overall response rate in labeling of 24%, there’s still room for improvement with combinations and use in earlier lines of therapy.
Melanoma therapy could take another leap forward with the development of another BRAF inhibitor, a MEK inhibitor, and late-stage trials testing combinations against both BRAF options alone.
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.